Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01 · 8-K

InspireMD Inc.

NSPRNASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “ Company ”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231 s…

Filed Nov 20, 2026Accepted Nov 20, 2026, 4:06 PM ESTCIK 1433607Accession 0001493152-26-053487
Share

Company context

InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Current securities

Historical securities (4)

Recent company filings

  1. 4 filingNov 17, 2026
  2. 4 filingNov 17, 2026
  3. 10-Q filingNov 16, 2026
  4. Entry into a Material Definitive Agreement · Other EventsNov 16, 2026
  5. 424B5 filingNov 16, 2026

Registered securities in this filing

InspireMD, Inc. · 8-K · Filed 2026-11-20

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
NSPR
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-11-20

Dimensions: Not supplied

Accession 000149315226053487 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “ Company ”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of Common Stock (the “ Common Warrants ”), pursuant to the Company’s effective automatic shelf registration statement on Form S-3 (File No. 333-286309) previously filed with the Securities and Exchange Commission (the “ SEC ”), raising approximately $34.9 million in net proceeds after deducting underwriting discounts and before offering expenses. Pursuant to the Underwriting Agreement, dated November 13, 2026 (the “ Underwriting Agreement ”), by and among the Company and Lake Street Capital Markets, LLC, as representative (the “ Representative ”) of the several underwriters named therein (collectively, the “ Underwriters ”), the Underwriters were granted a 30-day option (the “ Option ”) to purchase up to an additional 8,635,846 shares of Common Stock (the “ Option Shares ”) and/or Common Warrants to purchase up to 6,490,384 shares of Common Stock (the “ Option Common Warrants ”) from the Company on the same terms and conditions. On November 18, 2026, the Representative notified the Company that it had elected to exercise the Option in full. The offering of the Option Shares and Option Common Warrants closed on November 20, 2026, raising an additional approximately $5.3 million in net proceeds after deducting underwriting discounts and before offering expenses. The Option Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026, by and between the Company and Securities Transfer Corporation, as warrant agent.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.